sorafenib has been researched along with Sarcoma in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 22 (84.62) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Baldi, GG; Leonard, H; Stacchiotti, S; Tap, W; Zaffaroni, N | 1 |
| Berros, JP; Casado Herráez, A; Cubedo, R; de Juan, A; de Las Peñas, R; García Del Muro, X; Lavernia, J; López Pousa, A; Martín Broto, J; Martínez Trufero, J; Maurel, J | 1 |
| Bulman, M; Evans, DGR; Freemont, AJ; Linder, C; Mangham, DC; Smith, MJ; Wallace, A | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM | 1 |
| Afzal, A; Beckett, BR; Doung, YC; Hayden, JB; Holtorf, ML; Huang, W; Hung, AY; Jones, RL; Mansoor, A; Meyer, JM; Mori, M; Perlewitz, KS; Pommier, RF; Rodler, ET; Ryan, CW; Tudorica, A; Vetto, JT; Woodward, WJ | 1 |
| Ali, SM; Araujo, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Subbiah, V; Wang, K; Wang, WL; Westin, SN | 1 |
| Borys, D; Boutin, RD; Canter, RJ; Christensen, SD; Lee, LY; Li, CS; Monjazeb, AM; Olusanya, A; Tamurian, RM | 1 |
| Ferrari, S; Paioli, A; Palmerini, E | 1 |
| Aichler, M; Borgmann, DM; Feuchtinger, A; Hauck, SM; Huber, K; Keller, U; Li, Z; Schwaiger, M; Walch, A; Zitzelsberger, H | 1 |
| Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J | 1 |
| Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M | 1 |
| Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, P; Chaigneau, L; Chevreau, C; Collard, O; Cropet, C; Cupissol, D; Duffaud, F; Eberst, L; Gentet, JC; Le Cesne, A; Marec-Berard, P; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Thyss, A | 1 |
| Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
| Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E | 1 |
| Kato, S | 1 |
| Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD | 1 |
| Crowley, J; Leblanc, M; Rankin, C | 1 |
| Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C | 1 |
| Deville, JL; Duffaud, F; Huynh, T; Salas, S | 1 |
| Lekili, M; Muezzinoglu, T; Nese, N; Temeltas, G | 1 |
| Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M | 1 |
| Ancukiewicz, M; Boucher, Y; Demetri, GD; Duda, DG; Eder, JP; Jain, RK; Lahdenranta, J; Morgan, JA; Quek, R; Raut, CP | 1 |
| Dei Tos, AP; Del Vescovo, R; Frezza, AM; Santini, D; Schiavon, G; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB | 1 |
| Basso, U; Bertuzzi, A; Boglione, A; Comandone, A; De Sanctis, R; Giordano, L; Lutman, FR; Marcon, I; Santoro, A; Soto Parra, H; Stroppa, E | 1 |
| Strumberg, D | 1 |
8 review(s) available for sorafenib and Sarcoma
| Article | Year |
|---|---|
New Molecular Insights, and the Role of Systemic Therapies and Collaboration for Treatment of Epithelioid Hemangioendothelioma (EHE).
Topics: Hemangioendothelioma, Epithelioid; Humans; Prognosis; Retrospective Studies; Sarcoma; Sorafenib | 2023 |
Sarcoma in neurofibromatosis 2: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnosis, Differential; Doxorubicin; Fatal Outcome; Humans; Male; Neoplasm Grading; Neurofibromatosis 2; Neurofibromin 2; Palliative Care; Retroperitoneal Neoplasms; Sarcoma; SMARCB1 Protein; Sorafenib; Spinal Neoplasms; Young Adult | 2019 |
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2014 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sorafenib | 2005 |
13 trial(s) available for sorafenib and Sarcoma
| Article | Year |
|---|---|
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Ifosfamide; Intention to Treat Analysis; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Spain; Treatment Outcome; Young Adult | 2018 |
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Ifosfamide; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sarcoma; Sorafenib; Young Adult | 2014 |
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
Topics: Adult; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Preoperative Period; Radiography; Sarcoma; Sorafenib; Young Adult | 2013 |
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
Topics: Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; S100 Proteins; Sarcoma; Sequence Analysis, DNA; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Conformal; Sarcoma; Sorafenib | 2014 |
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyrroles; Registries; Sarcoma; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chordoma; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sarcoma; Sorafenib; Survival Rate | 2015 |
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib; Young Adult | 2009 |
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Demography; Female; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sarcoma; Sorafenib; Survival Rate; Vascular Neoplasms | 2012 |
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Capillary Permeability; Extracellular Fluid; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pressure; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sarcoma; Sorafenib; Vascular Endothelial Growth Factors | 2012 |
Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sarcoma; Sorafenib; Treatment Outcome | 2013 |
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sarcoma; Sorafenib | 2013 |
5 other study(ies) available for sorafenib and Sarcoma
| Article | Year |
|---|---|
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Immunohistochemistry; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2014 |
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2014 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
Multiple Histology Phase II Trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Computer Simulation; Humans; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sarcoma; Sorafenib; Treatment Outcome | 2009 |
Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib | 2010 |